Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
8 March 2017
Answer given by Ms Malmström on behalf of the Commission

The Commission has made clear from the start that changes to the EU's laws on intellectual property rights for pharmaceuticals, or to pricing and reimbursement regulations, are not part of the EU's objectives in the Transatlantic Trade and Investment Partnership (TTIP) negotiations.

The EU already has a solid and comprehensive intellectual property rights system that allows innovators to thrive and to remain among the most competitive globally. So the Commission believes there is no cause for concern in relation to TTIP. For the same reasons, the Commission is not considering any new regulations related to drug pricing.

At the same time, EU Member States have some of the most efficient and inclusive public health systems in the world. Nothing in TTIP will endanger Member States' rights to manage their health systems as they see fit.

If any do choose to allow American companies to enter their public health services markets (as indeed some already do), these companies will be subject to the same regulation as any other that operates in the market. So the Commission believes there is no cause for concern on this matter either.

Last updated: 14 March 2017Legal notice